[Form 4] Akero Therapeutics, Inc. Insider Trading Activity
Akero Therapeutics insider sale by CEO and director Andrew Cheng. The Form 4 reports that Mr. Cheng, who serves as President and CEO and is a company director, executed sales of common stock on 08/11/2025 pursuant to a Rule 10b5-1 trading plan dated August 16, 2024. The filing lists three dispositions of 10,795, 18,805 and 400 shares, each shown as sales, with weighted-average price ranges disclosed in the footnotes.
The footnotes state the shares were sold in multiple transactions at prices ranging $47.40鈥�$48.39, $48.41鈥�$49.39, and $49.43鈥�$49.44, respectively. The report also shows the amount of common stock beneficially owned following the reported transactions as 509,962, 491,157 and 490,757 shares on the corresponding lines. The Form 4 is signed by an attorney-in-fact and identifies the trades as executed under the 10b5-1 plan; no other financial or operational data is included.
Vendita da insider di Akero Therapeutics effettuata dal CEO e direttore Andrew Cheng. Il Form 4 riporta che il Sig. Cheng, che ricopre le cariche di Presidente e CEO e fa parte del consiglio di amministrazione, ha eseguito la vendita di azioni ordinarie il 08/11/2025 in conformit脿 a un piano di negoziazione Rule 10b5-1 datato August 16, 2024. La comunicazione elenca tre cessioni di 10,795, 18,805 e 400 azioni, tutte indicate come vendite, con fasce di prezzo ponderato mediate riportate nelle note a pi猫 di pagina.
Le note indicano che le azioni sono state vendute in pi霉 transazioni a prezzi compresi rispettivamente tra $47.40鈥�$48.39, $48.41鈥�$49.39 e $49.43鈥�$49.44. Il rapporto mostra inoltre la quantit脿 di azioni ordinarie possedute dopo le transazioni come 509,962, 491,157 e 490,757 azioni sulle rispettive righe. Il Form 4 猫 firmato da un procuratore e identifica le operazioni come eseguite secondo il piano 10b5-1; non sono inclusi altri dati finanziari o operativi.
Venta por insider de Akero Therapeutics realizada por el CEO y director Andrew Cheng. El Form 4 informa que el Sr. Cheng, quien se desempe帽a como Presidente y CEO y es director de la compa帽铆a, ejecut贸 ventas de acciones ordinarias el 08/11/2025 conforme a un plan de negociaci贸n Rule 10b5-1 fechado el August 16, 2024. La presentaci贸n enumera tres disposiciones de 10,795, 18,805 y 400 acciones, todas indicadas como ventas, con rangos de precio promedio ponderado divulgados en las notas al pie.
Las notas se帽alan que las acciones se vendieron en m煤ltiples transacciones a precios que oscilaron respectivamente entre $47.40鈥�$48.39, $48.41鈥�$49.39 y $49.43鈥�$49.44. El informe tambi茅n muestra la cantidad de acciones ordinarias de las que se tiene la propiedad beneficiaria tras las transacciones informadas: 509,962, 491,157 y 490,757 acciones en las l铆neas correspondientes. El Form 4 est谩 firmado por un apoderado e identifica las operaciones como ejecutadas bajo el plan 10b5-1; no se incluyen otros datos financieros u operativos.
Akero Therapeutics 雮措秬鞛� 毵る弰: CEO 瓴� 鞚挫偓 Andrew Cheng. Form 4 氤搓碃靹滌棎 霐半ゴ氅�, 靷灔 瓴� CEO鞚挫瀽 鞚挫偓搿� 鞛 欷戩澑 Cheng 鞌姅 08/11/2025鞐� August 16, 2024鞛� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 氤错喌欤茧ゼ 毵り皝頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 臧侁皝 毵る弰搿� 響滌嫓霅� 10,795, 18,805, 400欤检潣 靹� 瓯挫潣 觳橂秳鞚� 旮办灛霅橃柎 鞛堨溂氅�, 臧� 觳橂秳鞚� 臧�欷戫弶攴� 臧�瓴� 氩旍渼電� 臧侅＜鞐� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
臧侅＜鞐愲姅 頃措嫻 欤检嫕霌れ澊 臧侁皝 $47.40鈥�$48.39, $48.41鈥�$49.39, $49.43鈥�$49.44 氩旍渼鞚� 臧�瓴╈棎靹� 鞐煬 瓯挫溂搿� 韺愲Г霅橃棃雼り碃 鞝來榾 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 霕愴暅 氤搓碃霅� 瓯半灅 鞚错泟鞚� 鞁れ 氤挫湢 欤检嫕 靾橁皜 頃措嫻 頃氤勲 509,962, 491,157, 490,757欤茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑鞚� 靹滊獏頄堨溂氅� 瓯半灅臧� 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅� 瓴冹溂搿� 鞁濍硠霅橃柎 鞛堨溂氅�, 雼るジ 鞛路鞓侅梾 甏�霠� 雿办澊韯半姅 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Vente d'initi茅 d'Akero Therapeutics par le PDG et administrateur Andrew Cheng. Le Form 4 indique que M. Cheng, qui occupe les fonctions de Pr茅sident et PDG et est administrateur de la soci茅t茅, a r茅alis茅 des ventes d'actions ordinaires le 08/11/2025 conform茅ment 脿 un plan de n茅gociation Rule 10b5-1 dat茅 du August 16, 2024. Le d茅p么t mentionne trois cessions de 10,795, 18,805 et 400 actions, toutes qualifi茅es de ventes, avec des fourchettes de prix moyens pond茅r茅s d茅taill茅es en notes de bas de page.
Les notes pr茅cisent que les actions ont 茅t茅 vendues en plusieurs transactions 脿 des prix respectivement compris entre $47.40鈥�$48.39, $48.41鈥�$49.39 et $49.43鈥�$49.44. Le rapport indique 茅galement le nombre d'actions ordinaires d茅tenues apr猫s les transactions, 脿 savoir 509,962, 491,157 et 490,757 actions sur les lignes correspondantes. Le Form 4 est sign茅 par un mandataire et identifie les op茅rations comme ex茅cut茅es dans le cadre du plan 10b5-1 ; aucune autre donn茅e financi猫re ou op茅rationnelle n'est fournie.
Insider-Verkauf von Akero Therapeutics durch CEO und Direktor Andrew Cheng. Das Form 4 berichtet, dass Herr Cheng, der als President und CEO sowie als Direktor des Unternehmens fungiert, am 08/11/2025 Stammaktien gem盲脽 einem Rule 10b5-1-Handelsplan vom August 16, 2024 ver盲u脽ert hat. Die Einreichung listet drei Ver盲u脽erungen 眉ber 10,795, 18,805 und 400 Aktien, jeweils als Verk盲ufe ausgewiesen, mit in den Fu脽noten angegebenen gewogenen Durchschnittspreisbereichen.
Die Fu脽noten geben an, dass die Aktien in mehreren Transaktionen zu Preisen von jeweils $47.40鈥�$48.39, $48.41鈥�$49.39 und $49.43鈥�$49.44 verkauft wurden. Der Bericht zeigt au脽erdem die nach den gemeldeten Transaktionen wirtschaftlich gehaltenen Stammaktien in H枚he von 509,962, 491,157 und 490,757 Aktien in den entsprechenden Zeilen. Das Form 4 ist von einem Bevollm盲chtigten unterzeichnet und kennzeichnet die Trades als im Rahmen des 10b5-1-Plans ausgef眉hrt; weitere finanzielle oder operative Daten sind nicht enthalten.
- Sales executed under a Rule 10b5-1 trading plan, indicating the trades were pre-planned and comply with established insider-trading procedures.
- Detailed disclosure of price ranges and share counts in the footnotes provides transparency about execution.
- Chief executive officer sold shares, which may be perceived negatively by some investors despite being under a trading plan.
- No accompanying company operational or financial context is provided in the filing to explain the timing or rationale beyond the 10b5-1 plan.
Insights
TL;DR: CEO sales were executed under a pre-established 10b5-1 plan, which documents compliance but remains material to investors.
The filing shows that Andrew Cheng, President and CEO and a director, disposed of shares on 08/11/2025 under a Rule 10b5-1 plan dated August 16, 2024. The report discloses three separate sale entries with specified share counts and weighted-average price ranges in the footnotes. Because the transactions are pursuant to a pre-existing trading plan, they are procedurally compliant; however, insider sales by a senior executive are informationally relevant to investors and should be considered alongside other disclosures when assessing insider alignment.
TL;DR: Routine 10b5-1 sales by the CEO are reported; details provide execution dates, volumes and price ranges but no new operational metrics.
The Form 4 records three dispositions on 08/11/2025 for 10,795; 18,805; and 400 shares, with weighted-average price ranges disclosed in the accompanying footnotes. The filing includes the amounts of common stock beneficially owned following each reported transaction. There are no derivative transactions reported and no additional corporate events disclosed. From a disclosure standpoint, the filing supplies necessary trade specifics without providing performance or forward-looking information.
Vendita da insider di Akero Therapeutics effettuata dal CEO e direttore Andrew Cheng. Il Form 4 riporta che il Sig. Cheng, che ricopre le cariche di Presidente e CEO e fa parte del consiglio di amministrazione, ha eseguito la vendita di azioni ordinarie il 08/11/2025 in conformit脿 a un piano di negoziazione Rule 10b5-1 datato August 16, 2024. La comunicazione elenca tre cessioni di 10,795, 18,805 e 400 azioni, tutte indicate come vendite, con fasce di prezzo ponderato mediate riportate nelle note a pi猫 di pagina.
Le note indicano che le azioni sono state vendute in pi霉 transazioni a prezzi compresi rispettivamente tra $47.40鈥�$48.39, $48.41鈥�$49.39 e $49.43鈥�$49.44. Il rapporto mostra inoltre la quantit脿 di azioni ordinarie possedute dopo le transazioni come 509,962, 491,157 e 490,757 azioni sulle rispettive righe. Il Form 4 猫 firmato da un procuratore e identifica le operazioni come eseguite secondo il piano 10b5-1; non sono inclusi altri dati finanziari o operativi.
Venta por insider de Akero Therapeutics realizada por el CEO y director Andrew Cheng. El Form 4 informa que el Sr. Cheng, quien se desempe帽a como Presidente y CEO y es director de la compa帽铆a, ejecut贸 ventas de acciones ordinarias el 08/11/2025 conforme a un plan de negociaci贸n Rule 10b5-1 fechado el August 16, 2024. La presentaci贸n enumera tres disposiciones de 10,795, 18,805 y 400 acciones, todas indicadas como ventas, con rangos de precio promedio ponderado divulgados en las notas al pie.
Las notas se帽alan que las acciones se vendieron en m煤ltiples transacciones a precios que oscilaron respectivamente entre $47.40鈥�$48.39, $48.41鈥�$49.39 y $49.43鈥�$49.44. El informe tambi茅n muestra la cantidad de acciones ordinarias de las que se tiene la propiedad beneficiaria tras las transacciones informadas: 509,962, 491,157 y 490,757 acciones en las l铆neas correspondientes. El Form 4 est谩 firmado por un apoderado e identifica las operaciones como ejecutadas bajo el plan 10b5-1; no se incluyen otros datos financieros u operativos.
Akero Therapeutics 雮措秬鞛� 毵る弰: CEO 瓴� 鞚挫偓 Andrew Cheng. Form 4 氤搓碃靹滌棎 霐半ゴ氅�, 靷灔 瓴� CEO鞚挫瀽 鞚挫偓搿� 鞛 欷戩澑 Cheng 鞌姅 08/11/2025鞐� August 16, 2024鞛� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 氤错喌欤茧ゼ 毵り皝頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 臧侁皝 毵る弰搿� 響滌嫓霅� 10,795, 18,805, 400欤检潣 靹� 瓯挫潣 觳橂秳鞚� 旮办灛霅橃柎 鞛堨溂氅�, 臧� 觳橂秳鞚� 臧�欷戫弶攴� 臧�瓴� 氩旍渼電� 臧侅＜鞐� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
臧侅＜鞐愲姅 頃措嫻 欤检嫕霌れ澊 臧侁皝 $47.40鈥�$48.39, $48.41鈥�$49.39, $49.43鈥�$49.44 氩旍渼鞚� 臧�瓴╈棎靹� 鞐煬 瓯挫溂搿� 韺愲Г霅橃棃雼り碃 鞝來榾 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 霕愴暅 氤搓碃霅� 瓯半灅 鞚错泟鞚� 鞁れ 氤挫湢 欤检嫕 靾橁皜 頃措嫻 頃氤勲 509,962, 491,157, 490,757欤茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑鞚� 靹滊獏頄堨溂氅� 瓯半灅臧� 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅� 瓴冹溂搿� 鞁濍硠霅橃柎 鞛堨溂氅�, 雼るジ 鞛路鞓侅梾 甏�霠� 雿办澊韯半姅 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Vente d'initi茅 d'Akero Therapeutics par le PDG et administrateur Andrew Cheng. Le Form 4 indique que M. Cheng, qui occupe les fonctions de Pr茅sident et PDG et est administrateur de la soci茅t茅, a r茅alis茅 des ventes d'actions ordinaires le 08/11/2025 conform茅ment 脿 un plan de n茅gociation Rule 10b5-1 dat茅 du August 16, 2024. Le d茅p么t mentionne trois cessions de 10,795, 18,805 et 400 actions, toutes qualifi茅es de ventes, avec des fourchettes de prix moyens pond茅r茅s d茅taill茅es en notes de bas de page.
Les notes pr茅cisent que les actions ont 茅t茅 vendues en plusieurs transactions 脿 des prix respectivement compris entre $47.40鈥�$48.39, $48.41鈥�$49.39 et $49.43鈥�$49.44. Le rapport indique 茅galement le nombre d'actions ordinaires d茅tenues apr猫s les transactions, 脿 savoir 509,962, 491,157 et 490,757 actions sur les lignes correspondantes. Le Form 4 est sign茅 par un mandataire et identifie les op茅rations comme ex茅cut茅es dans le cadre du plan 10b5-1 ; aucune autre donn茅e financi猫re ou op茅rationnelle n'est fournie.
Insider-Verkauf von Akero Therapeutics durch CEO und Direktor Andrew Cheng. Das Form 4 berichtet, dass Herr Cheng, der als President und CEO sowie als Direktor des Unternehmens fungiert, am 08/11/2025 Stammaktien gem盲脽 einem Rule 10b5-1-Handelsplan vom August 16, 2024 ver盲u脽ert hat. Die Einreichung listet drei Ver盲u脽erungen 眉ber 10,795, 18,805 und 400 Aktien, jeweils als Verk盲ufe ausgewiesen, mit in den Fu脽noten angegebenen gewogenen Durchschnittspreisbereichen.
Die Fu脽noten geben an, dass die Aktien in mehreren Transaktionen zu Preisen von jeweils $47.40鈥�$48.39, $48.41鈥�$49.39 und $49.43鈥�$49.44 verkauft wurden. Der Bericht zeigt au脽erdem die nach den gemeldeten Transaktionen wirtschaftlich gehaltenen Stammaktien in H枚he von 509,962, 491,157 und 490,757 Aktien in den entsprechenden Zeilen. Das Form 4 ist von einem Bevollm盲chtigten unterzeichnet und kennzeichnet die Trades als im Rahmen des 10b5-1-Plans ausgef眉hrt; weitere finanzielle oder operative Daten sind nicht enthalten.
FAQ
What insider activity does the AKRO Form 4 report?
How many shares did the reporting person sell on the Form 4 for AKRO?
What price ranges were the AKRO shares sold at according to the Form 4?
Was the insider sale part of a pre-established trading plan for AKRO?
How much common stock did the reporting person beneficially own after the reported transactions?
